Who are Tenofovir disoproxil/emtricitabine/rilpivirine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Symtuza® (TAF/FTC/DRV/c), Lamivudine / Abacavir Sulfate, Regimen:TDF+3TC+EFV, Twice-daily ABC+3TC, AZT+3TC+ABV (Trizivir), AZT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tenofovir-disoproxil-emtricitabine-rilpivirine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Tenofovir disoproxil/emtricitabine/rilpivirine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tenofovir disoproxil/emtricitabine/rilpivirine (Tenofovir disoproxil/emtricitabine/rilpivirine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (NRTI + NNRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (NRTI + NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Tenofovir disoproxil/emtricitabine/rilpivirine (Tenofovir disoproxil/emtricitabine/rilpivirine) — Sheba Medical Center. This combination inhibits HIV reverse transcriptase and integrase to block viral replication and reduce viral load in HIV-infected patients.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tenofovir disoproxil/emtricitabine/rilpivirine TARGET	Tenofovir disoproxil/emtricitabine/rilpivirine	Sheba Medical Center	marketed	Antiretroviral combination (NRTI + NNRTI)	HIV reverse transcriptase
Symtuza® (TAF/FTC/DRV/c)	Symtuza® (TAF/FTC/DRV/c)	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4
Lamivudine / Abacavir Sulfate	Lamivudine / Abacavir Sulfate	GlaxoSmithKline	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Regimen:TDF+3TC+EFV	Regimen:TDF+3TC+EFV	National Center for AIDS/STD Control and Prevention, China CDC	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Twice-daily ABC+3TC	Twice-daily ABC+3TC	Medical Research Council	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
AZT+3TC+ABV (Trizivir)	AZT+3TC+ABV (Trizivir)	Fundacion SEIMC-GESIDA	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
AZT	AZT	Johns Hopkins Bloomberg School of Public Health	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (NRTI + NNRTI) class)

Sheba Medical Center · 1 drug in this class
Tuberculosis Research Centre, India · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tenofovir disoproxil/emtricitabine/rilpivirine — Competitive Intelligence Brief. https://druglandscape.com/ci/tenofovir-disoproxil-emtricitabine-rilpivirine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab